Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 18/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.76 |
| ▸ | FYN | P06241 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23299241 | 1.00 | PIM1 (0.80) | PIM1KCNH2FYN | |
| SCHEMBL20794682 | 0.89 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL19987115 | 0.89 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL102159 | 0.89 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL138794 | 0.89 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL23299246 | 0.88 | MKNK1 (0.65) | PIM1KCNH2FYN | |
| SCHEMBL23299207 | 0.87 | MKNK1 (0.67) | PIM1KCNH2FYN | |
| SCHEMBL16216094 | 0.86 | PIM1 (0.77) | PIM1KCNH2FYN | |
| SCHEMBL22421489 | 0.86 | PIM1 (0.64) | PIM1KCNH2FYN | |
| SCHEMBL16216065 | 0.86 | PIM1 (0.77) | PIM1KCNH2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9416132-B2 | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1599/4885FYN 227/4885 |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1832/4885FYN 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.